Progyny (NASDAQ:PGNY) Stock Bumped Down to Hold by Zacks Research

Progyny (NASDAQ:PGNY) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Monday, Zacks reports.

PGNY has been the subject of several other reports. KeyCorp boosted their price objective on Progyny from $30.00 to $35.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. JPMorgan Chase & Co. lifted their price objective on shares of Progyny from $27.00 to $30.00 and gave the stock a “neutral” rating in a research note on Friday, August 21st. Jefferies Financial Group set a $33.00 target price on Progyny in a research report on Tuesday, September 8th. Canaccord Genuity Group set a $35.00 price target on shares of Progyny in a research report on Friday, August 7th. Finally, Citizens Jmp raised their price objective on Progyny from $31.00 to $33.00 and gave the stock a “market outperform” rating in a research report on Tuesday, September 8th. Nine research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $34.36.

Progyny Stock Performance

NASDAQ PGNY opened at $28.58 on Monday. The company has a 50-day simple moving average of $26.44 and a 200-day simple moving average of $25.67. Progyny has a one year low of $16.10 and a one year high of $33.06. The firm has a market capitalization of $2.19 billion, a PE ratio of 31.07, a price-to-earnings-growth ratio of 1.92 and a beta of 1.02.

Progyny (NASDAQ:PGNY) last posted its earnings results on Thursday, August 6th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.33 by $0.22. The company had revenue of $350.51 million during the quarter, compared to analyst estimates of $349.05 million. Progyny had a return on equity of 15.98% and a net margin of 6.00%. The business’s revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company earned $0.19 earnings per share. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. Equities analysts forecast that Progyny will post 1.25 earnings per share for the current year.

Insider Activity

In related news, COO Melissa B. Cummings sold 1,879 shares of Progyny stock in a transaction on Wednesday, October 14th. The shares were sold at an average price of $28.00, for a total value of $52,612.00. Following the transaction, the chief operating officer owned 66,496 shares in the company, valued at $1,861,888. This trade represents a 2.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Allison Swartz sold 3,903 shares of the business’s stock in a transaction dated Wednesday, September 23rd. The stock was sold at an average price of $26.10, for a total value of $101,868.30. Following the transaction, the executive vice president directly owned 75,816 shares of the company’s stock, valued at $1,978,797.60. This represents a 4.90% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 17,282 shares of company stock valued at $475,790. Insiders own 9.90% of the company’s stock.

Hedge Funds Weigh In On Progyny

Several large investors have recently bought and sold shares of PGNY. Pinnacle Associates Ltd. bought a new stake in shares of Progyny in the third quarter valued at about $989,000. Nisa Investment Advisors LLC boosted its stake in shares of Progyny by 60.9% in the 3rd quarter. Nisa Investment Advisors LLC now owns 7,290 shares of the company’s stock valued at $184,000 after purchasing an additional 2,759 shares in the last quarter. Toth Financial Advisory Corp grew its position in Progyny by 21.3% during the 3rd quarter. Toth Financial Advisory Corp now owns 2,735 shares of the company’s stock worth $69,000 after acquiring an additional 480 shares during the last quarter. WINTON GROUP Ltd increased its position in Progyny by 266.7% in the 2nd quarter. WINTON GROUP Ltd now owns 251,834 shares of the company’s stock valued at $7,260,000 after acquiring an additional 183,163 shares in the last quarter. Finally, Engineers Gate Manager LP increased its stake in shares of Progyny by 5.6% in the 2nd quarter. Engineers Gate Manager LP now owns 152,757 shares of the company’s stock valued at $4,404,000 after buying an additional 8,156 shares during the period. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Company Profile

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.